Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 3c

Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results

August 4, 2022 6:00 AM EDT

Net revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS® (voclosporin) for 2022

Continued increases in LUPKYNIS Patients on Treatment; Steady Conversion Rates and Payor Coverage

EMA review of LUPKYNIS remains on track with decision expected by the end of Q3 2022

$391.7 million of cash and investments as of June 30, 2022

Conference call to be hosted today at 8:30 a.m. ET

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:... More